BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1. [verwijderd] 5 november 2006 12:50

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   PS; ga eindelijk wat echte spreiding doen......ben van plan volg wk 10k te kopen om max naar 20k te gaan in loop vd volg weken....wellicht dipt ie nog voor de cijfers?
2. [verwijderd] 5 november 2006 13:50

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   leguaan3 schreef:

   PS; ga eindelijk wat echte spreiding doen......ben van plan volg wk 10k te kopen om max naar 20k te gaan in loop vd volg weken....wellicht dipt ie nog voor de cijfers?
   

   legi , ik vind het niet erg mijn mening te geven,
   houd je echter aub in op andere draadjes waar ik ook geinvesteerd ben (je snapt wel wat ik bedoel)
   brand/enthousiasmeer amerikanen maar ipv hiero
   
   quo kopen:
   technisch lijkt 4,80 nu een zeer sterke resistance
   er zijn nog 13 miljoen shorts, die kunnen nog wat proberen
   echter de tijd dringt voor hun
   denk echt dat tuissen 4,80-5,00 een goede koopzone is
   boven de 5$ is ie al gespiked, gaat ie zeker naar terug en dan ook meer institutionele interesse
   advies los van spreiding: gewoon gestaffeld kopen
3. [verwijderd] 5 november 2006 21:37

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Crack,
   SHORT DNDN 17%? ENCY 16%; voor mij essentiele cijfers....voor wat de opwaartse potentie van een aandeel....mn als er belangrijke gebeurtenissen zoals indiening /goedkeuring FDA toestanden voor de deur staan.... dan vallen ze over elkaar heen om te coveren.....geloof dat dit voor ENCY wat korter voor de deur staat..maar in ieder gavl ook voor DNDN.... als je het percentage short staande aandelen bij INSM vergelijkt...eigenlijk bar weinig...heb je een verklaring????
   gr leg
4. [verwijderd] 5 november 2006 21:44

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Hey Lucky,
   Leef je nog??? hoe is het met jou man..... mis de goede oude grumpy Lucide van het GTCB draadje zo langzamerhand wel;heb het afgelopen jaar wel steeds je postings op Ya-ZOO gevolgd...je een tweetjes met Willem.....post je ook op het DNDN board??? Ondanks alle shit die je me toewenste toch vervelend je nergens meer op IEX te kunnen lezen...altijd weer vermakelijk....het leek af en toe wel KOEFNOEN!!! hehehehehe
   gr en de beste wensen LEUGUAAN!
5. [verwijderd] 8 november 2006 13:23

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Dendreon Reports Third Quarter 2006 Financial Results
   
   -- Management Will Host Conference Call at 11:00 am ET --
   
   SEATTLE, WA, November 8, 2006 - Dendreon Corporation (Nasdaq: DNDN) today reported
   results for the quarter ended September 30, 2006. Revenue for the third quarter of
   2006 was $84,000 compared to $58,000 for the quarter ended September 30, 2005.
   Revenue for the nine months ended September 30, 2006 was $187,000 compared to
   $173,000 for the nine months ended September 30, 2005.
   
   Dendreon's total operating expenses for the third quarter of 2006 were $21.7 million
   compared to $21.0 million in 2005. Dendreon's total operating expenses for the nine
   months ended September 30, 2006 were $73.6 million compared to $60.4 million for the
   same period in 2005. Operating expenses for the three and nine months ended
   September 30, 2006 included stock-based employee compensation expense of $1.2
   million and $3.0 million, respectively.
   
   The net loss for the quarter ended September 30, 2006 was $20.7 million, or $0.29
   per share, compared to a net loss of $19.7 million, or $0.33 per share, for the
   quarter ended September 30, 2005. The net loss for the nine months ended September
   30, 2006 was $70.2 million, or $0.98 per share, compared to $56.7 million, or $0.96
   per share for the nine months ended September 30, 2005.
   
   Cash, cash equivalents and short-term and long-term investments at September 30,
   2006 totaled $92.6 million.
   
   Recent Highlights:
   
   - Submitted clinical and non-clinical sections of rolling Biologics License
   Application (BLA) submission to U.S. Food and Drug Administration (FDA) for
   PROVENGE(R) (sipuleucel-T) for the treatment of patients with asymptomatic,
   metastatic, androgen-independent (also known as hormone-refractory) prostate cancer.
   The Company plans to complete the BLA submission with the chemistry, manufacturing
   and controls (CMC) section prior to the end of the year.
   
   - Presented new exploratory analyses from Phase 3 D9901 study that showed a
   significant improvement in prostate cancer specific survival for patients who
   received PROVENGE. The overall survival benefit does not appear to be due to any
   imbalances in the treatment arms or subsequent use and timing of chemotherapy.
   
   - Presented results from exploratory analysis of Phase 3 Studies (D9901 and D9902A)
   showing a significant correlation between cumulative CD54 upregulation and survival
   for patients treated with PROVENGE.
   
   "We have made tremendous progress during the third quarter. The submission of the
   first portion of our BLA for PROVENGE is a significant accomplishment for the
   Company," said Mitchell H. Gold, M.D., president and chief executive officer of
   Dendreon. "The additional data analyses from our Phase 3 trials presented at various
   scientific meetings this quarter further support the clinical activity of PROVENGE
   and enhance our BLA submission. We remain focused on completing our BLA submission
   to the FDA this year."
   
   Conference Call Information
   
   Dendreon will host a conference call today at 8:00 a.m. PT, 11:00 a.m. ET. To access
   the live call, dial 800-817-4887 (domestic) or +1-913-981-4913 (international). The
   call will also be audio webcast and will be available from the Company's website at
   www.dendreon.com under the "Investor/Webcasts and Presentations" section. A phone
   replay of the call will be available for 3 days by calling 888-203-1112 (domestic)
   or +1-719-457-0820 (international); Passcode: 4189364.
   
   About Dendreon
   
   Dendreon Corporation is a biotechnology company whose mission is to target cancer
   and transform lives through the discovery, development and commercialization of
   novel therapeutics that harness the immune system to fight cancer. The Company
   applies its expertise in antigen identification, engineering and cell processing to
   produce active cellular immunotherapy product candidates designed to stimulate a
   cell-mediated immune response. Active cellular immunotherapy holds promise because
   it may provide patients with a meaningful clinical benefit, such as survival,
   combined with low toxicity. The Company has headquarters in Seattle and is traded on
   The Nasdaq Stock Market(R) under the symbol DNDN. For more information about the
   Company and its programs, visit www.dendreon.com.
   
   Except for historical information contained herein, this news release contains
   forward-looking statements that are subject to risks and uncertainties surrounding
   the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and
   uncertainties surrounding the presentation of data to the FDA and approval of
   product applications by the FDA and risks and uncertainties inherent in the process
   of discovering, developing and commercializing drugs that are safe and effective for
   use as human therapeutics. Factors that may cause such differences include risks
   related to our limited operating history, risks associated with completing our
   clinical trials, the risk that the safety and/or efficacy results of a clinical
   trial for PROVENGE will not support an application for a biologics license, the risk
   that the FDA may interpret data differently than we do or require more data or a
   more rigorous analysis of data than expected, the risk that the FDA will not approve
   a product for
   which a biologics license has been applied, the risk that the results of a clinical
   trial for PROVENGE or other product may not be indicative of results obtained in a
   later clinical trial, risks that we may lack the financial resources and access to
   capital to fund required clinical trials or commercialization of PROVENGE, our
   dependence on the efforts of third parties, and our dependence on intellectual
   property. Further information on the factors and risks that could affect Dendreon's
   business, financial condition and results of operations are contained in Dendreon's
   public disclosure filings with the U.S. Securities and Exchange Commission, which
   are available at www.sec.gov.
   
   Contact:
   Monique Greer
   Sr. Director, Corporate Communications
   Dendreon Corporation
   (206) 829-1500
   
   * Please see attached document for financial information.
   
6. [verwijderd] 8 november 2006 16:29

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Belangrijke resultaten: p11 resultaten!!!
7. [verwijderd] 8 november 2006 16:30

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Dendreon Announces Preliminary Results from PROTECT (P-11) Study
   
   -- PROVENGE Prolongs PSA Doubling Time in Patients with Early Stage Prostate Cancer --
   
   SEATTLE, WA, November 8, 2006 - Dendreon Corporation (Nasdaq: DNDN) today announced preliminary results from its ongoing PROTECT (P-11) clinical trial for PROVENGE(R) (sipuleucel-T) in patients with non-metastatic androgen-dependent (hormone sensitive) prostate cancer. The study was designed to explore the biologic activity of PROVENGE in patients with recurrent prostate cancer prior to the development of metastatic disease. The study results demonstrate a prolongation in prostate-specific antigen (PSA) doubling time (PSADT) for patients who received PROVENGE compared to placebo. PSADT is currently considered to be one of the best predictors of clinical outcome in patients with PSA recurrence following primary therapy. Dendreon plans to submit the data for presentation at a future upcoming medical meeting.
   
   Study Design:
   
   The study, known as PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11, is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and biologic activity of PROVENGE in men with non-metastatic androgen-dependent prostate cancer who have had a PSA recurrence following surgical removal of the prostate. A total of 176 patients at 19 sites in the United States were randomized 2:1 to receive PROVENGE or placebo following a 3-month course of hormonal therapy. Patients were then followed with serial PSA measurements to evaluate the impact of PROVENGE on PSA and PSADT. At the time of biochemical progression, defined as a PSA of 3 ng/mL or greater, men became eligible for one booster infusion of either PROVENGE or placebo in accordance with the treatment arm to which they were randomized. Patients continue to be followed for the clinical endpoints of time to distant failure, which typically would be the appearance of a positive bone scan, and for
   overall survival.
   
   Preliminary Study Results:
   
   - Biochemical Endpoints: As specified in the protocol, an analysis of PSADT calculated from 90 days following randomization until biochemical progression or the initiation of systemic therapy demonstrated that patients randomized to receive PROVENGE had a 35 percent increase in their PSADT compared to patients randomized to receive placebo (p-value = 0.046). To adjust for potential variations in the rate of testosterone recovery following hormonal therapy, the PSADT was also calculated after a patient's testosterone returned to baseline levels. This analysis demonstrated that patients randomized to receive PROVENGE had a 49 percent increase in their PSADT compared to patients randomized to receive placebo (p-value = 0.038). In addition, although not statistically significant, there was a positive trend in the overall delay in the time to reach a PSA level of 3.0 ng/ml for patients in the PROVENGE arm compared to patients in the placebo arm.
   
   - Clinical Endpoints: There was a delay of approximately 27 percent (HR = 0.73) in the time to distant metastasis for patients randomized to receive PROVENGE compared to patients randomized to receive placebo. Because only 16 percent of patients in the study had a distant failure event at the time of this analysis, it is not yet powered to evaluate statistical significance. Per protocol, patients will continue to be followed for the clinical endpoints of distant failure and overall survival.
   
   - Immunology Data: In a subset of patients the immune response against the recombinant antigen PA2024 was measured at baseline (before dosing with PROVENGE or placebo) and at 4 and 13 weeks following randomization (after dosing). PA2024 is a fusion protein composed of prostatic acid phosphatase (PAP), and a cytokine, GM-CSF. T-cell responses were monitored by measuring T-cell proliferation by recording the stimulation index (SI) and by measuring the number of T-cells that secrete interferon gamma by ELISPOT. By both methods, and at both the 4 and 13 week time points, significant responses were seen in the PROVENGE treated patients, but not in the patients assigned to receive placebo. For example, at 13 weeks, the median SI was 118.5 in the PROVENGE arm compared to 2.3 in the placebo arm (p-value <0.0001). The immune response was also monitored at the time of boosting to assess the durability and persistence of the immune response. These analyses, conducted at a median time of 21
   months following randomization, demonstrated that the immune response continued to persist at significant levels (p-value <0.0001) in the PROVENGE arm compared to the placebo arm. The median SI observed in the PROVENGE arm prior to boosting was 93.7 and 13 weeks following a single boosting infusion of PROVENGE, the median SI was 221.8, suggesting that the immune response can be boosted to even higher levels.
   
   - Safety: Consistent with the Company's other studies conducted to date, treatment with PROVENGE was generally well tolerated. The most common adverse reactions associated with PROVENGE were chills, fever, headache, fatigue and vomiting. These events were primarily low grade events, with a short duration lasting 1 to 2 days following infusion.
   
   "The initial results from this randomized study suggest a potential role for PROVENGE early in the natural evolution of prostate cancer," said Mark Frohlich, M.D., vice president of clinical affairs at Dendreon. "We are encouraged by the effect of PROVENGE on PSA doubling time, an important predictor of clinical outcome in this patient population. We plan on following these patients for the clinical endpoints of overall survival and time to distant failure. More importantly in the near term, the data from the patients in this study will supplement our overall safety database for PROVENGE as part of our current BLA submission for men with advanced androgen-independent prostate cancer."
   
   Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 232,000 new cases of prostate cancer diagnosed each year. More than 30,000 men die each year of the disease.
   
   About PROVENGE
   
   PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.
   
   Dendreon has submitted one of two portions of a rolling submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for PROVENGE as an active cellular immunotherapy treatment for men with asymptomatic, metastatic, androgen-independent prostate cancer. The Company expects to submit the chemistry, manufacturing and controls (CMC) section of the BLA prior to the end of 2006. If approved, PROVENGE would become the first commercially available active cellular immunotherapy for advanced hormone-refractory prostate cancer.
   
   About Dendreon
   
   Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercializ
8. [verwijderd] 8 november 2006 16:31

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   By: bioshortsqueezer Send PM Profile Ignore Recommend Add To Favorites
   P11 results - Wow
   Wow. The results are stunning, better than I expected. To show a statistically significant delay in PSA doubling time in early-stage prostate cancer is no small feat, considering the large variability in this disease. The standard deviation in PSA doubling time is large, so the effect of any treatment will also have to be large in order to rise above the statistical noise. The immunological data back up the effect as well. I was expecting perhaps only some trends in the right direction that had not yet reached statistical significance. Safety is great, and that data will go into the current submission for androgen-independent (late-stage) prostate cancer.
   
   In re our discussion of accelerated approval yesterday based on surrogate endpoints -- PSA doubling time and maybe even the immunological response would qualify. DNDN actually could conceivably apply for accelerated approval for Provenge in hormone-dependent prostate cancer, the second most common cancer around the world, a cancer which may become the most common cancer as men live longer, RIGHT NOW. If this were another biotech with only these P11 results and nothing else, they would be announcing such an intention to file for accelerated approval (and their market cap would have gone up by hundreds of millions today). I doubt DNDN will do that, because they have our hands full with the filing for AIPC, and they probably want to let P11 run its planned course after the whole 9902-9902A-9902B protocol-changing mess.
   
   The management and PR are severely understating the results. "The initial results from this randomized study suggest a potential role for PROVENGE early in the natural evolution of prostate cancer," said Mark Frohlich, M.D., vice president of clinical affairs at Dendreon. "We are encouraged by the effect of PROVENGE on PSA doubling time, an important predictor of clinical outcome in this patient population." SUGGEST A POTENTIAL ROLE? WE ARE ENCOURAGED? Let me translate this into Cell Genesys- or Antigenics-speak. "The results from our large, blinded, randomized, multi-center Phase III trial unequivocably demonstrate that Provenge is a safe and effective treatment for early-stage prostate cancer. In combination with our previous Phase III trial results in late-stage prostate cancer, we have proven that Provenge is safe and effective in all types of prostate cancer, the second-most common cancer in the United States and throughout the world, and the most common cancer in men. We are confident that the same rationally designed immunotherapeutic approach can be extended to treat a variety of other cancers, including breast cancer, with higher efficacy and much lower side-effects than existing treatments." ("We are encouraged" would be something Cell Genesys or Antigenics would say as part of "We are encouraged by our results that failed to show a statistically significant effect but do show that if we look hard enough for a subset of patients we can find a few that seem to respond better than sick historical controls, so we will continue to make our big promises, and it would be great if you will all buy some of the stocks we are selling in our upcoming offering.")
   
   Clearly DNDN is a company that takes a long-term view rather than hyping. Perhaps that's why the stock is only up 2% as I write. If I hadn't bought a large block at $4.5 recently and made DNDN 33% of my portfolio, I would buy more, IMHO. It's unusual to get positive statistically significant indications of final success of a trial without Wall Street catching on and hyping it up. And while DNDN's understated manner not be the most financially rewarding right away for current shareholders, we can sleep soundly knowing that the rug is not likely to get pulled out from under us.
   
   
   
9. [verwijderd] 8 november 2006 17:03

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   prachtige timing vlak voor de cc
   =)
   
   By: skcotswonki Send PM Profile Ignore Recommend Add To Favorites
   P-11 is now short poison...Gold can finish it with clear guidance on financing...
   The shorts have had three outs.
   
   One, a massive market crash, unlikely in the time frame they have.
   
   Two, disappointing P-11 data culminating in a large volume selloff. This was their best hope and it just went up in smoke.
   
   Third, a highly dilutive financing at low valustions. Gold can erase this hope on the call.
   
   The shorts problem is they are stuck with over 12 million shares and an FDA approval luming in the near future. Now there is only one short strategy, how best to cover. If Gold kills the cheap financing route, then only a massive market crash can save them from huge losses.
   
   
   
10. [verwijderd] 8 november 2006 21:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dendreon reports larger Q3 loss
    Wednesday November 8, 3:11 pm ET
    
    Biotechnology company Dendreon Corp. reported a larger third-quarter loss compared to the same period a year ago.
    Dendreon (NASDAQ: DNDN - News), which is developing treatments for cancer, said its net loss for the quarter ended Sept. 30 was $20.7 million, compared to $19.7 million for the third quarter 2005.
    
    The Seattle-based company said third-quarter revenue was $84,000, compared to $58,000 the same period a year ago.
    
    In a separate announcement, Dendreon said preliminary results from an ongoing phase three clinical trial for its lead drug candidate, Provenge, indicated that drug delayed the progression of early-stage prostate cancer in trial patients.
    
    Published November 8, 2006 by the Puget Sound Business Journal
    
    biz.yahoo.com/bizj/061108/1373148.htm...
11. [verwijderd] 8 november 2006 22:49

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    AH painting
    
    After Hours
    Last: $ 5.46 After Hours
    High: $ 5.59
    After Hours
    Volume: 30,326 After Hours
    Low: $ 5.29
    
    After Hours
    Time (ET) After Hours
    Price After Hours
    Share Volume
    16:25 $ 5.46 100
    16:09 $ 5.44 100
    16:09 $ 5.44 100
    16:09 $ 5.44 100
    16:07 $ 5.59 27,400
    16:04 $ 5.38 1,326
    16:00 $ 5.29 100
    16:00 $ 5.45 100
    
12. [verwijderd] 9 november 2006 18:02

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Crack,
    ik ben vandaag ingestapt met een plukje 2500stuks op 5,34.....
    ik heb een goed gevoel maar dit aandeel is wel vast in handen v shorters zeg, ben blij dat ik er nu inzit, misschien iets te duur gekocht maar ik ga er niet al te groot in hier, wilde eerst met 10 a 15k erin maar koop liever ENCY......indien in januari ENCY levert, dan ga ik alsbog groot erin, FDA beslissing ergens in zomer 2007 is het niet???
    gr leg
13. [verwijderd] 9 november 2006 18:15

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tja,
    shorters.... te hoog ingestapt.....
14. [verwijderd] 9 november 2006 19:36

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    leguaan3 schreef:

    Tja,
    shorters.... te hoog ingestapt.....
    

    valt mee legi
    stockcharts.com/h-sc/ui?s=DNDN&p=D&yr...
    
    hij zal waarschinnlijk de bovenste bollinger band gaan volgen, grote kans op, dat is de bovenste rode lijn die eromheen kronkelt
15. [verwijderd] 9 november 2006 20:34

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=leguaan3]
    Tja,
    shorters.... te hoog ingestapt.....
    [/quote]
    valt mee legi
    stockcharts.com/h-sc/ui?s=DNDN&p=D&yr...
    
    hij zal waarschinnlijk de bovenste bollinger band gaan volgen, grote kans op, dat is de bovenste rode lijn die eromheen kronkelt
    

    Vooralsnog gaat het erg rap naar beneden jeeezzzzzz, gezien het nieuws gisteren...toch wel erg vreemd...dit aandeel is echt in de greep vd shorters...zou goed terugkunnen naar de 4,5 regionen zeg...gisteren hihg5,7?????
16. [verwijderd] 9 november 2006 20:41

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    leguaan3 schreef:

    [quote=crackedtooth]
    [quote=leguaan3]
    Tja,
    shorters.... te hoog ingestapt.....
    [/quote]
    valt mee legi
    stockcharts.com/h-sc/ui?s=DNDN&p=D&yr...
    
    hij zal waarschinnlijk de bovenste bollinger band gaan volgen, grote kans op, dat is de bovenste rode lijn die eromheen kronkelt
    [/quote]
    
    Vooralsnog gaat het erg rap naar beneden jeeezzzzzz, gezien het nieuws gisteren...toch wel erg vreemd...dit aandeel is echt in de greep vd shorters...zou goed terugkunnen naar de 4,5 regionen zeg...gisteren hihg5,7?????
    

    zijn shorts
    
    1e support 5,21
    2e support 5,10
    
    verwacht niet dat ie nog substantieel onder de 5$ gaat
    
    en CMC sectie BLA voor eind dit jaar
17. [verwijderd] 10 november 2006 14:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    shorts al een paar manipulatieve downgrades gedaan, meest nootwaardige UBS
    (SAC=grote short in dndn) dit alles net na juist zeer goede data, zo voorspelbaar die shorts
    
    vandaag vervolg p11 data
    
    biz.yahoo.com/prnews/061110/sff019.ht...
    
    Dendreon Announces New Data Analysis Presented at Chemotherapy Foundation Symposium
    Friday November 10, 8:20 am ET
    
    SEATTLE and NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN - News) today announced the presentation of data from an exploratory analysis of Phase 3 Studies (D9901 and D9902A) that showed a prolonged survival benefit for patients initially treated with PROVENGE® (sipuleucel-T) who then went on to receive docetaxel chemotherapy after disease progression. PROVENGE is the Company's lead investigational active cellular immunotherapy for the treatment of advanced prostate cancer.
    ADVERTISEMENT
    
    
    The abstract, entitled "Defining the Optimal Role of Immunotherapy and Chemotherapy: Advanced Prostate Cancer Patients Who Receive Sipuleucel-T (PROVENGE) Followed by Docetaxel Derive Greatest Survival Benefit," was presented today at the Chemotherapy Foundation Symposium in New York by Daniel Petrylak, M.D., associate professor of medicine at the New York-Presbyterian Hospital at the Columbia University Medical Center.
    
    "The results of this analysis suggest that the use of PROVENGE as a first-line treatment followed by the chemotherapy docetaxel upon disease progression may provide patients with a substantially prolonged survival benefit," said Dr. Petrylak. "This analysis provides valuable clinical insight as to how the treatment of men with advanced prostate cancer will likely evolve with the potential introduction of new products like sipuleucel-T that complement the currently available treatment regimens for men with advanced prostate cancer."
    
    The analysis was conducted by evaluating the integrated data from the Phase 3 Studies D9901 and D9902A to assess the influence of PROVENGE on clinical outcome in patients who received docetaxel chemotherapy after primary treatment with PROVENGE. Specifically, the analysis evaluated survival data from 82 patients who received docetaxel chemotherapy following initial treatment with either PROVENGE or placebo. The median survival observed in the PROVENGE treated patients who subsequently received docetaxel was 34.5 months compared to 25.4 months for patients randomized to receive placebo who went on to receive docetaxel, a difference of 9.1 months (HR=1.90; p-value=0.023). Approximately 68 percent of the patients randomized to receive placebo also subsequently participated in a cross-over salvage protocol that allowed them to receive active cellular immunotherapy with APC8015F, a version of PROVENGE generated from cryopreserved cells. The median survival was 25.7 months for patients who received APC8015F followed by docetaxel. In contrast, the median survival was 20.2 months for patients who received placebo only and subsequent treatment with docetaxel, a 14.3 month difference compared to 34.5 month median survival seen in the patients who received initial treatment with PROVENGE followed by docetaxel. These three groups appeared to be well balanced based on their baseline prognostic factors, using an independently validated predictive nomogram (Halabi, et al. Prognostic model for predicting survival in men with HRPC: Journal of Clinical Oncology, 2003; 21(7): 1232-7).
    
    Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 232,000 new cases of prostate cancer diagnosed each year. More than 30,000 men die each year of the disease.
    
    
18. [verwijderd] 10 november 2006 15:54

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hoe kan die nou met zulke berichten zakken?
    Soms weet ik het niet meer.
19. [verwijderd] 10 november 2006 15:55

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    tonpa schreef:

    Hoe kan die nou met zulke berichten zakken?
    Soms weet ik het niet meer.
    

    13 miljoen shorts
    simpel antwoord
20. [verwijderd] 10 november 2006 16:10

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    tonpa schreef:

    Hoe kan die nou met zulke berichten zakken?
    Soms weet ik het niet meer.
    

    Je haalt mij de woorden uit de mond??? erg vreemd...weet dus niet wanner ik nu bij moet kopen.....wacht nog ff af